The dilemma of single revenue model and excessive reliance on drug sales is hard to overcome.Due to low gross margin, it's difficult to generate decent net profit margin. Pre-IPO valuation is too high
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.